title: Comparative study on Salmonella mutagenicity and on cytogenetic and antineoplastic effects induced by cyclophosphamide and 3-aminobenzamide in cells of three transplantable tumours in vivo.
abstract: Synergistically enhanced sister chromatid exchange (SCE) frequency by cyclophosphamide (CP) was observed when L1210 lymphoid tumor cells were exposed in vivo to a non-toxic concentration of 3-aminobenzamide (3-AB). Additive effects in SCE induction in vivo were observed when either Ehrlich ascites tumor (EAT) cells or P388 lymphocytic leukemia cells treated with CP were exposed to 3-AB in vivo. 3-AB enhanced the survival time of L1210 tumor bearing BDF1 mice treated with CP. However, the combined CP plus 3-AB treatment did not increase the survival of either EAT BALB/c- or P388 BDF1-tumor bearing mice compared with the effect on survival by CP alone. Therefore the in vivo differential antitumor effect, by CP in conjunction with 3-AB, appears to correlate well with the in vivo differential effect on cytogenetic damage caused by the combined CP plus 3-AB treatment. In the Salmonella typhimurium/mammalian microsome test CP appears to have a dose dependent ability to induce base-pair substitutions in strains TA 100 and TA 1535 and frameshift mutations in strains TA 98 and TA 1537. Both types of mutation were synergistically increased in the presence of 3-AB.
authors.affiliation: Department of General Biology and Genetics, Faculty of Medicine Aristotle University, Thessaloniki, Greece.
authors.forename: P
authors.initials: P
authors.lastname: Eliopoulos
authors.forename: D
authors.initials: D
authors.lastname: Mourelatos
authors.forename: J
authors.initials: J
authors.lastname: Dozi-Vassiliades
mesh_terms: D000818:Animals; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use / Q000633:toxicity; D001549:Benzamides / Q000494:pharmacology*; D002286:Carcinoma, Ehrlich Tumor / Q000188:drug therapy / Q000235:genetics; D003520:Cyclophosphamide / Q000627:therapeutic use* / Q000633:toxicity; D016368:Frameshift Mutation; D007939:Leukemia L1210 / Q000188:drug therapy* / Q000235:genetics; D051379:Mice; D009152:Mutagenicity Tests; D000067856:Poly(ADP-ribose) Polymerase Inhibitors; D012485:Salmonella typhi / Q000187:drug effects; D012854:Sister Chromatid Exchange; D014407:Tumor Cells, Cultured
chemical_list: D001549:Benzamides; D000067856:Poly(ADP-ribose) Polymerase Inhibitors; C025160:3-aminobenzamide; D003520:Cyclophosphamide